Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Cytokeratin, pan Antibody (KRT/457), Alexa Fluor™ 594, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP247669AF594
Description
Cytokeratin, pan Monoclonal specifically detects Cytokeratin, pan in Human, Mouse, Rat, Porcine, Amphibian, Bovine, Guinea Pig, Goat, Monkey samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunofluorescence.Specifications
Cytokeratin, pan | |
Monoclonal | |
Alexa Fluor 594 | |
50 mM sodium borate with 0.05% sodium azide | |
Mouse | |
Protein A or G purified | |
Apoptosis, Cancer, Cell Biology, Cellular Markers, Signal Transduction | |
3848 | |
Human, Mouse, Rat, Pig, Amphibian, Bovine, Guinea Pig, Goat, Monkey | |
IgG1 κ |
Western Blot, Flow Cytometry, Immunohistochemistry, Immunohistochemistry (Paraffin), Immunofluorescence | |
KRT/457 | |
Western Blot, Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunofluorescence | |
KRT1 | |
This Cytokeratin, pan Antibody (KRT/457) was developed against keratin-enriched preparation from cultured human epithelial cells | |
0.1 mL | |
Primary | |
Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum antibody, which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. | |
Store at 4°C in the dark. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction